ANI Pharmaceuticals’ (ANIP) Buy Rating Reaffirmed at HC Wainwright

ANI Pharmaceuticals (NASDAQ:ANIP)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a research report issued on Monday,Benzinga reports. They presently have a $94.00 target price on the specialty pharmaceutical company’s stock. HC Wainwright’s price target would suggest a potential upside of 50.42% from the company’s previous close.

ANIP has been the topic of several other research reports. StockNews.com raised shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday. Jefferies Financial Group assumed coverage on ANI Pharmaceuticals in a research report on Friday. They set a “buy” rating and a $80.00 target price for the company. Guggenheim increased their price target on ANI Pharmaceuticals from $84.00 to $86.00 and gave the company a “buy” rating in a research note on Wednesday, March 5th. JPMorgan Chase & Co. assumed coverage on shares of ANI Pharmaceuticals in a research report on Wednesday, March 12th. They issued an “overweight” rating and a $85.00 price target on the stock. Finally, Leerink Partners initiated coverage on ANI Pharmaceuticals in a report on Wednesday, December 11th. They set an “outperform” rating and a $80.00 target price on the stock. Two analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $79.75.

ANI Pharmaceuticals Price Performance

NASDAQ:ANIP opened at $62.49 on Monday. ANI Pharmaceuticals has a 52 week low of $52.50 and a 52 week high of $70.81. The company has a market capitalization of $1.36 billion, a price-to-earnings ratio of -113.62 and a beta of 0.63. The company has a 50-day moving average of $58.40 and a 200-day moving average of $58.06. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.97 and a current ratio of 2.74.

Insiders Place Their Bets

In other news, SVP Krista Davis sold 1,000 shares of the firm’s stock in a transaction that occurred on Friday, February 21st. The stock was sold at an average price of $60.20, for a total value of $60,200.00. Following the completion of the sale, the senior vice president now directly owns 68,624 shares of the company’s stock, valued at $4,131,164.80. This trade represents a 1.44 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CFO Stephen P. Carey sold 7,500 shares of the stock in a transaction dated Tuesday, December 17th. The shares were sold at an average price of $55.79, for a total transaction of $418,425.00. Following the completion of the transaction, the chief financial officer now directly owns 154,468 shares in the company, valued at $8,617,769.72. The trade was a 4.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 10,700 shares of company stock valued at $610,201 in the last three months. 12.70% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in ANIP. US Bancorp DE grew its position in ANI Pharmaceuticals by 842.9% during the fourth quarter. US Bancorp DE now owns 594 shares of the specialty pharmaceutical company’s stock worth $33,000 after buying an additional 531 shares in the last quarter. KBC Group NV grew its position in ANI Pharmaceuticals by 89.2% during the 4th quarter. KBC Group NV now owns 1,273 shares of the specialty pharmaceutical company’s stock worth $70,000 after acquiring an additional 600 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new position in shares of ANI Pharmaceuticals in the fourth quarter valued at approximately $166,000. Zurcher Kantonalbank Zurich Cantonalbank increased its position in ANI Pharmaceuticals by 24.2% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,971 shares of the specialty pharmaceutical company’s stock valued at $177,000 after acquiring an additional 579 shares during the period. Finally, Rafferty Asset Management LLC acquired a new stake in ANI Pharmaceuticals in the fourth quarter valued at $200,000. Institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.